Objective: Vanishing white matter (VWM) is an autosomal recessive leukoencephalopathy characterized by slowly progressive ataxia and spasticity with additional stress-provoked episodes of rapid and major deterioration. The disease is caused by mutations in the genes encoding the subunits of eukaryotic initiation factor 2B, which is pivotal in translation of mRNAs into proteins. The disease onset, clinical severity, and disease course of VWM vary greatly. The influence of genotype and gender on the phenotype is unclear.
or severe phenotype. 12,14 -16 In addition, striking intrafamilial phenotypic heterogeneity has been reported, 2, 15, 16, 18 suggesting that environmental or other genetic factors also influence the phenotype. Recently, an effect of gender was suggested. 19 Many different mutations have been described in VWM and most patients are compound heterozygous for 2 different mutations in 1 of the 5 disease genes. 20 We addressed the question whether the clinical phenotype of compound heterozygous patients is determined by the mildest mutation, the most severe mutation, or both. Our hypothesis was that both mutations determine the phenotype. In addition, we hypothesized that the disease severity is different in men and women.
METHODS Study design. We performed a crosssectional observational study and included all available patients with specific mutations from our VWM patient database until February 2009. The database contains all patients referred to VU University Medical Center for mutational analysis for VWM.
Standard protocol approvals, registrations, and patient consents. Written informed consent for research was obtained from all patients, or guardians of the patients, participating in the study. Approval of the ethical standards committee was received for retrospective analysis of clinical information, collected by questionnaires.
Mutation-based selection of patients.
Approximately 70% of the patients with VWM in our database have mutations in EIF2B5 and 30% have mutations in EIF2B1-4. We focused on the patients with EIF2B5 mutations. P.Arg113His in EIF2B5 is the most frequent mutation and the mildest known mutation. In the homozygous state it is almost invariably associated with adulthood onset and protracted disease course. 14 -16 To answer whether the mildest mutation, the most severe mutation, or the combination of both mutations determines the phenotype, we compared the phenotypes of patients homozygous for p.Arg113His, compound-heterozygous for p.Arg113His and another mutation (p.Arg113His/ p.any), and patients in whom p.Arg113His was not involved (p.any/p.any).
Another relatively large group in our database has the so-called Dutch founder mutation (p.Thr91Ala in EIF2B5). 5 The next largest group has a mutation involving arginine (Arg) at position 339 of EIF2B5. At this position we have observed amino acid substi-tutions to Gln, Trp, and Pro (collectively referred to as p.Arg339any). To investigate the effect of 2 different EIF2B5 mutations on the phenotype, we selected patients homozygous for p.Arg113His, patients homozygous for p.Thr91Ala, and patients with one of these mutations in the compound heterozygous state with p.Arg339any. None of our patients is homozygous for p.Arg339any.
Phenotype. We used clinical questionnaires to be filled in by either the family or the physician following the patient. In order to avoid the problem of differences in rating the disability, we chose robust clinical outcomes for the present study to characterize the phenotype: age at onset, age at loss of walking without support, and age at death. The disease onset was considered the age at which the first neurologic symptom appeared. Delayed early development was not included. Patients were scored as having lost independent walking when they could no longer walk without support and not when they started to use a wheelchair for part of the time. If the patients never walked without support, they were scored as having lost the ability of unsupported walking at the age of 1.5 years. Hence, if patients died before the age of 1.5, they were not included in the analysis of loss of walking without support. The disease duration was defined as the time between the disease onset and the latest clinical observation. Both disease duration and age were used for analysis of Kaplan-Meier curves.
To test whether the disease severity differs between men and women, we analyzed male/female differences in the entire group of EIF2B5-mutated patients and in the groups of patients with the EIF2B5 mutations specified above.
Patients with another disease affecting neurologic function in addition to VWM were excluded. Patients for whom no follow-up data were known were also excluded from the analysis. Statistical analysis. Summary statistics (mean and SD, the latter in parentheses) of clinical variables are given in years. Noncensored clinical variables of patient subgroups were compared using either the 2-sample Student t test or 1-way analysis of variance. The cumulative probabilities of individuals to lose the ability to walk without support or to die, in relation to the disease duration or the age of the patient, were estimated through Kaplan-Meier curves. Logrank statistics were performed to compare subgroups with respect to censored clinical variables. Individuals not reaching an event (i.e., age at loss of independent walking or death) within the study period were considered to be censored. Analyses were performed using SPSS for Windows version 15.
RESULTS Patients. Of the 184 patients in our database, 126 (68%) had mutations in EIF2B5. The number of patients, age at onset, age at loss of independent walking, and age at death for the different groups are given in tables 1 and 2. Sixty-two patients were male and 64 female. The gender and genotype of all patients included in the study can be found in table e-1 on the Neurology ® Web site at www.neurology.org.
Three of the 126 patients were excluded from further analysis: 2 because of comorbidity (i.e., Down syndrome and a developmental anomaly in the form of encephalocele, abnormal gyration, and neuronal heterotopias) and 1 because of a lack of clinical information.
Comparison of p.Arg113His/p.Arg113His, p.Arg113His/ p.any, and p.any/p.any. Comparing the patients homozygous for p.Arg113His with the patients compound heterozygous for this mutation, differences were found concerning average age at onset ( p Ͻ 0.001), average age at loss of unsupported walking ( p Ͻ 0.001), and average age at death ( p ϭ 0.012) in favor of patients homozygous for p.Arg113His (table  1) . Comparison of the Kaplan-Meier plots demonstrated that patients homozygous for p.Arg113His retained the ability to walk independently longer, both in age ( p Ͻ 0.001) and in disease duration ( p Ͻ 0.001), and had a longer survival in age ( p Ͻ 0.001) and disease duration ( p ϭ 0.009) than patients compound heterozygous for p. Arg113His (figure 1 ).
Comparing the patients homozygous for p.Arg113His with the patients with 2 other EIF2B5 mutations than p.Arg113His (p.any/p.any), we found differences in average age at onset ( p ϭ 0.001), age at loss of unsupported walking ( p Ͻ 0.001), and age at death ( p Ͻ 0.001) in favor of patients homozygous for p.Arg113His. Log-rank tests confirmed that patients homozygous for p.Arg113His retained the ability to walk independently longer, both in age ( p Ͻ 0.001) and in disease duration ( p ϭ 0.001), and had a longer survival in age ( p ϭ 0.002) and disease duration ( p ϭ 0.013) than the p.any/p.any group ( figure 1 ).
There were no differences between patients who were compound heterozygous with 1 p.Arg113His mutation and the patients with 2 other mutations (figure 1).
Comparison of p.Arg113His, p.Thr91Ala, and p.Arg339any. We found a difference in age at onset between patients homozygous for p.Arg113His and patients homozygous for p.Thr91Ala ( p ϭ 0.003), the first group doing better than the second group (table 2) . We found a trend for age at loss of unsupported walking ( p ϭ 0.092) and age at death ( p ϭ 0.323), the first group doing better. Comparing Kaplan-Meier plots demonstrated that patients homozygous for p.Arg113His retained the ability to walk independently longer in age ( p ϭ 0.05), but not in disease duration ( p ϭ 0.451), than patients homozygous for p.Thr91Ala (figure 2). There was no difference with respect to overall survival.
Patients with p.Arg113His/p.Arg339any and patients with p.Thr91Ala/p.Arg339any differed in average age at loss of unsupported walking ( p ϭ 0.008), the first group doing better. The same trend was demonstrated for age at onset ( p ϭ 0.077). The number of patients with p.Arg113His/p.Arg339any who died was too small for a valid comparison. Comparing Kaplan-Meier plots confirmed that patients with p.Arg113His/p.Arg339any retained the ability to walk longer in age ( p Ͻ 0.001) and tended to have a longer disease duration ( p ϭ 0.092). There was a difference in age at death ( p ϭ 0.039). Also the disease duration until death tended to be longer for patients with p.Arg113His/p.Arg339any than for patients with p.Thr91Ala/p.Arg339any ( p ϭ 0.089).
Influence of gender in EIF2B5-mutated patients. Age at onset, age at loss of independent walking, and age at death for females and males in the different groups are given in table e-2.
An imbalance between males and females was only noticed in the subgroup of patients homozygous for p.Arg113His. The ratio was 8 males/15 females in this group, vs 26/23 in the p.Arg113His/p.any a Values are mean Ϯ SD (no. of patients for whom data were available and an event had occurred). Within the entire group of EIF2B5-mutated patients (males/females ϭ 60/63), differences were found between males and females concerning average age at onset ( p ϭ 0.01) and average age at loss of unsupported walking ( p ϭ 0.01) in the sense that females did better. There was no difference in average age at death ( p ϭ 0.256). Comparison of the Kaplan-Meier plots revealed that females tended to retain the ability to walk longer in age ( p ϭ 0.090). There were no differences between males and females in survival.
We also analyzed the subgroups of patients with p.Arg113His/p.Arg113His, p.Arg113His/p.any, p.Thr91Ala/p.Thr91Ala, p.Arg113His/p.Arg339any, or p.Thr91Ala/p.Arg339any separately. In the group of patients homozygous for p.Arg113His, the age at loss of unsupported walking was higher in females than in males ( p ϭ 0.072). Females with p.Arg113His/ p.Arg339any tended to have a later onset ( p ϭ 0.109) and to lose the ability to walk later ( p ϭ 0.107). The latter was also found in the log-rank test ( p ϭ 0.098). No other gender-related trends were found in the different subgroups.
DISCUSSION In our study of the influence of genotype on phenotype in VWM, we focused on patients with EIF2B5 mutations, being the largest group. We selected the 3 most frequent mutations: p.Arg113His, p.Thr91Ala, and p.Arg339any, associated with a mild, mild to intermediate, and severe phenotype, respectively. We treated patients with p.Arg339any as a single group, although p.Arg339Trp, p.Arg339Pro, and p.Arg339Gln may not have exactly the same effect on the phenotype. Mutations at this position are, however, consistently associated with a severe disease. No patients homozygous for p.Arg339any are known and homozygosity for the mutation may be incompatible with life.
Our findings demonstrate that patients homozygous for p.Arg113His have a milder disease than patients compound heterozygous for p.Arg113His. This indicates that the phenotype is not determined by the mildest mutation alone, but either by the most severe mutation or by a combination of both mutations. Patients homozygous for p.Arg113His tend to have a milder disease than patients homozygous for p.Thr91Ala. Patients homozygous for p.Arg113His and homozygous for p.Thr91Ala have a milder disease than patients with p.Arg113His/p.Arg339any and patients with p.Thr91Ala/p.Arg339any. Patients with p.Arg113His/p.Arg339any have a milder phenotype than patients with p.Thr91Ala/p.Arg339any. These findings indicate that the phenotype is not determined by the most severe mutation alone, but by the effect of both mutations.
Figure 1 Survival
Patients homozygous for the p.Arg113His mutation survive longer than patients with p.Arg113His/p.any and p.any/p.any. There is no difference between patients with p.Arg113His/p.any and p.any/p.any. The curves are showing the cumulative probability of patients to survive estimated from the age at onset.
Figure 2 Ability to walk
Patients homozygous for the p.Arg113His mutation retain the ability to walk independently longer than patients with p.Thr91Ala/p.Thr91Ala, p.Arg113His/p.Arg339any, and p.Thr91Ala/p.Arg339any. The latter do worse in the order mentioned. The curves are showing the cumulative probability of the ability to walk independently estimated from birth.
This conclusion is important for clinicians and genetic counselors providing information to patients and families. One should be careful, however, with definitive predictions for new patients. Further studies on larger groups of patients would make this conclusion more certain.
Recently, an overrepresentation of females was found among adult patients with VWM, mainly patients with p.Arg113His. 19 A higher susceptibility of females to disease expression was suggested, assuming that affected males remain asymptomatic for a longer period of time. The present study, however, demonstrates that females with mutations in EIF2B5 tend to do better than males. All differences found were in favor of the females. Larger subgroups of patients must be studied before it can be concluded that females do better for all mutations. Strikingly, and in agreement with this recent study, 19 we also found an overrepresentation of females among the p.Arg113Hismutated patients. It is at present unexplained why there are more female patients with this mutation.
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